SCHEMBL13600083

SCHEMBL13600083

COC(=O)c1ccc(C(O)c2ccccn2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
KDM4E B2RXH2 5/20 0.52
POLB P06746 1/20 0.52
SCD O00767 1/20 0.52
PKM P14618 1/20 0.49
RAB9A P51151 4/20 0.48
NPC1 O15118 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 2/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CYP3A4 P08684 2/20 0.46
ABCB11 O95342 1/20 0.46
LMNA P02545 1/20 0.46
ESR1 P03372 1/20 0.46
ADRA2A P08913 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23535674 0.85 MAPT (0.52) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL30041537 0.85 MAPT (0.52) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL3916979 0.84 MAPT (0.51) MAPTKDM4EPOLBPKMRAB9A
SCHEMBL866718 0.79 TSHR (0.64) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL30251598 0.79 TSHR (0.64) MAPTPOLBRAB9ANPC1SMN1; SMN2
SCHEMBL4408604 0.79 CA1 (0.66) MAPTKDM4ERAB9ATSHRCA12
SCHEMBL2401530 0.78 SLC10A1 (0.54) MAPTKDM4ESCDPKMRAB9A
SCHEMBL31143712 0.78 SLC10A1 (0.54) MAPTKDM4ESCDPKMRAB9A
SCHEMBL23610031 0.78 SLC10A1 (0.54) MAPTKDM4ESCDPKMRAB9A
SCHEMBL31143624 0.78 SLC10A1 (0.54) MAPTKDM4ESCDPKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7638531-B2 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION (US) 2009-12-29 US disclosed
US-7638531-B2 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION (US) 2009-12-29 US disclosed
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION 2007-07-19 US disclosed
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists SCHERING CORPORATION 2007-07-19 US disclosed
WO-2007075629-A2 PHENOXYPIPERIDINES AND ANALOGS THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS SCHERING CORPORATION (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167435-A1 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists HRH4, HRH3, HRH2 MAPT 2125/4885KDM4E 2254/4885POLB 3858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.